ALERT 🚨: TMDX performance check moved +28.01% since 2026-05-25. We chose this because TransMedics has a differentiated organ-preservation platform, integrated logistics and a...
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
TMDX Stock Analysis 2026-05-25 | Narrowit.com
Open the Narrowit.com stock research report for TMDX dated 2026-05-25, including valuation, performance, risk factors, entry strategy, and scorecard analysis.
www.narrowit.com
November 7, 2026 at 1:28 AM
ALERT 🚨: TMDX performance check moved +28.01% since 2026-05-25. We chose this because TransMedics has a differentiated organ-preservation platform, integrated logistics and a...
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
November 9, 2026 at 6:31 AM
The consensus take is priced in. This one is not.
$TMDX
$TMDX at $80.41: short squeeze setup, path to $89.80 (+11.7%), killed by a close back under the 20-day average with short volume drying up.
Full letter ↓
#TMDX #stockanalysis
https://stockmarketloop.com/r/GiRIzeLTav/
$TMDX
$TMDX at $80.41: short squeeze setup, path to $89.80 (+11.7%), killed by a close back under the 20-day average with short volume drying up.
Full letter ↓
#TMDX #stockanalysis
https://stockmarketloop.com/r/GiRIzeLTav/
The consensus take is priced in. This one is not.
$TMDX at $80.41: short squeeze setup, path to $89.80 (+11.7%), killed by a close back under the 20-day average with short volume drying up.
stockmarketloop.com
November 6, 2026 at 2:42 PM
The consensus take is priced in. This one is not.
$TMDX
$TMDX at $80.41: short squeeze setup, path to $89.80 (+11.7%), killed by a close back under the 20-day average with short volume drying up.
Full letter ↓
#TMDX #stockanalysis
https://stockmarketloop.com/r/GiRIzeLTav/
$TMDX
$TMDX at $80.41: short squeeze setup, path to $89.80 (+11.7%), killed by a close back under the 20-day average with short volume drying up.
Full letter ↓
#TMDX #stockanalysis
https://stockmarketloop.com/r/GiRIzeLTav/
🫀 #$TMDX +13.9% after-hours! TransMedics smashed Q3: EPS $0.46 vs $0.29, revenue $203M (+41% YoY), service revenue +60%. Full-year guide raised to $764–774M. 🚀 @TransMedics @Nasdaq Stock closed -5.2% first, and EPS is still down 30% YoY. Thin after-hours liquidity can reverse, 💰 #TMDX #Earnings
November 5, 2026 at 10:53 PM
#TMDX TransMedics Reports Third Quarter 2026 Financial Results
https://www.stocktitan.net/news/TMDX/trans-medics-reports-third-quarter-2026-financial-hxt47j5i474w.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/TMDX/trans-medics-reports-third-quarter-2026-financial-hxt47j5i474w.html?utm_source=stocktitan-bluesky&utm_medium=social
TransMedics Reports Third Quarter 2026 Financial Results
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 5, 2026 at 9:02 PM
#TMDX TransMedics Reports Third Quarter 2026 Financial Results
https://www.stocktitan.net/news/TMDX/trans-medics-reports-third-quarter-2026-financial-hxt47j5i474w.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/TMDX/trans-medics-reports-third-quarter-2026-financial-hxt47j5i474w.html?utm_source=stocktitan-bluesky&utm_medium=social
🚨 $TMDX
On November 5, 2026, TransMedics Group, Inc. issued a press release announcing the Company’s financial results for the quarter ended September 30, 2026. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
On November 5, 2026, TransMedics Group, Inc. issued a press release announcing the Company’s financial results for the quarter ended September 30, 2026. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
SEC Filing: TMDX
Click to view the official SEC document.
www.sec.gov
November 5, 2026 at 9:03 PM
🚨 $TMDX
On November 5, 2026, TransMedics Group, Inc. issued a press release announcing the Company’s financial results for the quarter ended September 30, 2026. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
On November 5, 2026, TransMedics Group, Inc. issued a press release announcing the Company’s financial results for the quarter ended September 30, 2026. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
📉 CNDT targets 1.5 net leverage in 2028 with ASCEND plan.
📈 QSI guides 2026 OpEx under $87M with Proteus Q2 launch.
📈 TMDX raised 2026 revenue to $774M with 2027 catalysts.
📈 CSTL sees $395M 2026 revenue on TissueCypher volume.
📈 QSI guides 2026 OpEx under $87M with Proteus Q2 launch.
📈 TMDX raised 2026 revenue to $774M with 2027 catalysts.
📈 CSTL sees $395M 2026 revenue on TissueCypher volume.
November 6, 2026 at 6:28 AM
📉 CNDT targets 1.5 net leverage in 2028 with ASCEND plan.
📈 QSI guides 2026 OpEx under $87M with Proteus Q2 launch.
📈 TMDX raised 2026 revenue to $774M with 2027 catalysts.
📈 CSTL sees $395M 2026 revenue on TissueCypher volume.
📈 QSI guides 2026 OpEx under $87M with Proteus Q2 launch.
📈 TMDX raised 2026 revenue to $774M with 2027 catalysts.
📈 CSTL sees $395M 2026 revenue on TissueCypher volume.
TransMedics (TMDX) reportó ingresos de US$203 millones en el Q3'26 (+41% interanual), por encima de lo esperado. EPS de US$0,46. Subió su guidance de ingresos para el año a US$764-774 millones. El protocolo de la FDA habilita 90 pacientes más para ENHANCE Heart.
November 6, 2026 at 12:20 AM
TransMedics (TMDX) reportó ingresos de US$203 millones en el Q3'26 (+41% interanual), por encima de lo esperado. EPS de US$0,46. Subió su guidance de ingresos para el año a US$764-774 millones. El protocolo de la FDA habilita 90 pacientes más para ENHANCE Heart.
Clive Anderson is on today's Book Club shows.acast.com/rhlstp/episo...
Buy his book here uk.bookshop.org/p/books/i-th...
Clip
www.youtube.com/watch?v=TMdX...
Buy his book here uk.bookshop.org/p/books/i-th...
Clip
www.youtube.com/watch?v=TMdX...
Clive Anderson on his, and humanity's, history with dogs - from RHLSTP Book Club 199
YouTube video by Richard Herring
www.youtube.com
October 30, 2026 at 9:04 AM
Clive Anderson is on today's Book Club shows.acast.com/rhlstp/episo...
Buy his book here uk.bookshop.org/p/books/i-th...
Clip
www.youtube.com/watch?v=TMdX...
Buy his book here uk.bookshop.org/p/books/i-th...
Clip
www.youtube.com/watch?v=TMdX...
🚨 $TMDX
Araujo Fernando N. (See Remarks) reported special transactions (Non-P/S).
Araujo Fernando N. (See Remarks) reported special transactions (Non-P/S).
SEC Filing: TMDX
Click to view the official SEC document.
www.sec.gov
October 30, 2026 at 8:16 PM
🚨 $TMDX
Araujo Fernando N. (See Remarks) reported special transactions (Non-P/S).
Araujo Fernando N. (See Remarks) reported special transactions (Non-P/S).
#TMDX TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
https://www.stocktitan.net/news/TMDX/trans-medics-reports-inducement-grants-under-nasdaq-listing-rule-uwr6tk0j0tyy.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/TMDX/trans-medics-reports-inducement-grants-under-nasdaq-listing-rule-uwr6tk0j0tyy.html?utm_source=stocktitan-bluesky&utm_medium=social
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics (Nasdaq: TMDX) granted stock options and restricted stock units to nine employees on October 28, 2026, as employment inducements.The awards cover options to purchase 71,815 shares at an exercise price of $66.90 per share and 47,924 restricted stock units (RSUs). Chief Financial Officer Fernando Araujo received options covering 34,419 shares and 22,969 RSUs. The Compensation Committee approved the grants under the Inducement Plan and Nasdaq Listing Rule 5635(c)(4). Options have a 10-year term, with 25% vesting after the first year of employment and the remainder monthly over the next three years. RSUs vest 25% on each of the first four employment anniversaries. All vesting requires continued service.
www.stocktitan.net
October 30, 2026 at 8:05 PM
#TMDX TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
https://www.stocktitan.net/news/TMDX/trans-medics-reports-inducement-grants-under-nasdaq-listing-rule-uwr6tk0j0tyy.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/TMDX/trans-medics-reports-inducement-grants-under-nasdaq-listing-rule-uwr6tk0j0tyy.html?utm_source=stocktitan-bluesky&utm_medium=social
$GOGO · $TMDX 📝
TransMedics Group, Inc. selected Gogo Inc.'s Gogo Galileo HDX to equip 22 Embraer Phenom 300E organ-transport aircraft with inflight connectivity.
Timely market event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
TransMedics Group, Inc. selected Gogo Inc.'s Gogo Galileo HDX to equip 22 Embraer Phenom 300E organ-transport aircraft with inflight connectivity.
Timely market event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
October 27, 2026 at 11:03 AM
$GOGO · $TMDX 📝
TransMedics Group, Inc. selected Gogo Inc.'s Gogo Galileo HDX to equip 22 Embraer Phenom 300E organ-transport aircraft with inflight connectivity.
Timely market event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
TransMedics Group, Inc. selected Gogo Inc.'s Gogo Galileo HDX to equip 22 Embraer Phenom 300E organ-transport aircraft with inflight connectivity.
Timely market event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
$HAE-1 $DBX-1 $TSLL-1 $SPCH-1 $CVNA-1 $SW-1 $CRBG-1 $ORCL-1 $IVW-1 $FLNC-1 $U-1 $AIN-1 $HYMC-1 $HUYA-1 $DIS-1 $BAC-1 $XLC-1 $SPXU-1 $OKTA-1 $NRG-1 $CORD-1 $CAKE-1 $XLE-1 $XLY-1 $UVXY-1 $NVDL-1 $LIN-1 $COPX-1 $UPRO-1 $SANM-1 $JHX-1 $QLD-1 $CEG-1 $ADSK-1 $CHWY-1 $TMDX-1 $RCL-1
October 27, 2026 at 8:38 PM
$HAE-1 $DBX-1 $TSLL-1 $SPCH-1 $CVNA-1 $SW-1 $CRBG-1 $ORCL-1 $IVW-1 $FLNC-1 $U-1 $AIN-1 $HYMC-1 $HUYA-1 $DIS-1 $BAC-1 $XLC-1 $SPXU-1 $OKTA-1 $NRG-1 $CORD-1 $CAKE-1 $XLE-1 $XLY-1 $UVXY-1 $NVDL-1 $LIN-1 $COPX-1 $UPRO-1 $SANM-1 $JHX-1 $QLD-1 $CEG-1 $ADSK-1 $CHWY-1 $TMDX-1 $RCL-1
Random Stock
Ticker: $TMDX
Company: TransMedics Group, Inc.
Sector: Healthcare
Industry: Medical Devices
# Employees: 898
Recent Close: $76.52
52-Week High: $156.00
52-Week High Date: 12-02-2025
% Off 52-Week High: -50.95%
52-Week Low: $60.10
Ticker: $TMDX
Company: TransMedics Group, Inc.
Sector: Healthcare
Industry: Medical Devices
# Employees: 898
Recent Close: $76.52
52-Week High: $156.00
52-Week High Date: 12-02-2025
% Off 52-Week High: -50.95%
52-Week Low: $60.10
October 16, 2026 at 8:00 AM
Random Stock
Ticker: $TMDX
Company: TransMedics Group, Inc.
Sector: Healthcare
Industry: Medical Devices
# Employees: 898
Recent Close: $76.52
52-Week High: $156.00
52-Week High Date: 12-02-2025
% Off 52-Week High: -50.95%
52-Week Low: $60.10
Ticker: $TMDX
Company: TransMedics Group, Inc.
Sector: Healthcare
Industry: Medical Devices
# Employees: 898
Recent Close: $76.52
52-Week High: $156.00
52-Week High Date: 12-02-2025
% Off 52-Week High: -50.95%
52-Week Low: $60.10
ALERT 🚨: TMDX performance check moved +13.40% since 2026-05-25. We chose this because TransMedics has a differentiated organ-preservation platform, integrated logistics and a...
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
TMDX Stock Analysis 2026-05-25 | Narrowit.com
Open the Narrowit.com stock research report for TMDX dated 2026-05-25, including valuation, performance, risk factors, entry strategy, and scorecard analysis.
www.narrowit.com
October 13, 2026 at 12:19 AM
ALERT 🚨: TMDX performance check moved +13.40% since 2026-05-25. We chose this because TransMedics has a differentiated organ-preservation platform, integrated logistics and a...
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
ALERT 🚨: TMDX performance check moved +17.61% since 2026-05-25. We chose this because TransMedics has a differentiated organ-preservation platform, integrated logistics and a...
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
TMDX Stock Analysis 2026-05-25 | Narrowit.com
Open the Narrowit.com stock research report for TMDX dated 2026-05-25, including valuation, performance, risk factors, entry strategy, and scorecard analysis.
www.narrowit.com
October 8, 2026 at 12:27 AM
ALERT 🚨: TMDX performance check moved +17.61% since 2026-05-25. We chose this because TransMedics has a differentiated organ-preservation platform, integrated logistics and a...
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
ALERT 🚨: TMDX performance check moved +20.39% since 2026-05-25. We chose this because TransMedics has a differentiated organ-preservation platform, integrated logistics and a...
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
TMDX Stock Analysis 2026-05-25 | Narrowit.com
Open the Narrowit.com stock research report for TMDX dated 2026-05-25, including valuation, performance, risk factors, entry strategy, and scorecard analysis.
www.narrowit.com
October 6, 2026 at 12:25 AM
ALERT 🚨: TMDX performance check moved +20.39% since 2026-05-25. We chose this because TransMedics has a differentiated organ-preservation platform, integrated logistics and a...
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
#$TMDX TransMedics is transforming the $10 billion organ transplant market with a vertically integrated aviation and technology model and kidney upside ahead, though investors must tolerate near-term margin compression as it scales in Europe.
intickers.com/reports/tmdx/
intickers.com/reports/tmdx/
TransMedics Group, Inc. (TMDX) Stock Analysis | InTickers
TransMedics is transforming the $10 billion organ transplant market with a vertically integrated aviation and…
intickers.com
October 3, 2026 at 10:40 PM
#$TMDX TransMedics is transforming the $10 billion organ transplant market with a vertically integrated aviation and technology model and kidney upside ahead, though investors must tolerate near-term margin compression as it scales in Europe.
intickers.com/reports/tmdx/
intickers.com/reports/tmdx/
#$TMDX TD Cowen maintains Buy with $120 price target on TransMedics.
- Rating and PT unchanged following latest update
- $120 target implies significant upside from current levels
- Analyst conviction holds despite recent volatility
- Rating and PT unchanged following latest update
- $120 target implies significant upside from current levels
- Analyst conviction holds despite recent volatility
October 2, 2026 at 1:06 PM
#$TMDX TD Cowen maintains Buy with $120 price target on TransMedics.
- Rating and PT unchanged following latest update
- $120 target implies significant upside from current levels
- Analyst conviction holds despite recent volatility
- Rating and PT unchanged following latest update
- $120 target implies significant upside from current levels
- Analyst conviction holds despite recent volatility
🚨 $TMDX
Araujo Fernando N. (See Remarks) filed Form 3 reporting no initial stock ownership.
Araujo Fernando N. (See Remarks) filed Form 3 reporting no initial stock ownership.
SEC Filing: TMDX
Click to view the official SEC document.
www.sec.gov
September 29, 2026 at 8:15 PM
🚨 $TMDX
Araujo Fernando N. (See Remarks) filed Form 3 reporting no initial stock ownership.
Araujo Fernando N. (See Remarks) filed Form 3 reporting no initial stock ownership.
ALERT 🚨: TMDX performance check moved +20.02% since 2026-05-25. We chose this because TransMedics has a differentiated organ-preservation platform, integrated logistics and a...
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
TMDX Stock Analysis 2026-05-25 | Narrowit.com
Open the Narrowit.com stock research report for TMDX dated 2026-05-25, including valuation, performance, risk factors, entry strategy, and scorecard analysis.
www.narrowit.com
September 29, 2026 at 12:18 AM
ALERT 🚨: TMDX performance check moved +20.02% since 2026-05-25. We chose this because TransMedics has a differentiated organ-preservation platform, integrated logistics and a...
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
ALERT 🚨: TMDX performance check moved +26.63% since 2026-05-25. We chose this because TransMedics has a differentiated organ-preservation platform, integrated logistics and a...
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
TMDX Stock Analysis 2026-05-25 | Narrowit.com
Open the Narrowit.com stock research report for TMDX dated 2026-05-25, including valuation, performance, risk factors, entry strategy, and scorecard analysis.
www.narrowit.com
September 22, 2026 at 12:23 AM
ALERT 🚨: TMDX performance check moved +26.63% since 2026-05-25. We chose this because TransMedics has a differentiated organ-preservation platform, integrated logistics and a...
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
https://www.narrowit.com/investment-analysis/stock/tmdx-2026-05-25
#InvestmentPerformance #TMDX #Stock #MarketUpdate
🚨📣 #insidertrading Weill David bought $109.1K of $TMDX on 2026-09-11
Insider performance (2020-24):
🟢1d: 2%
🟢3d: 8%
🟢5d: 1%
🔴1m: -15%
🟢3m: 13%
🟢6m: 27%
🟢1y: 159%
total trade: 1
$SPY $QQQ $DIA $VIX
#stock
#stockmarket #NASDAQ #NYSE #OTC
Insider performance (2020-24):
🟢1d: 2%
🟢3d: 8%
🟢5d: 1%
🔴1m: -15%
🟢3m: 13%
🟢6m: 27%
🟢1y: 159%
total trade: 1
$SPY $QQQ $DIA $VIX
#stock
#stockmarket #NASDAQ #NYSE #OTC
September 14, 2026 at 10:31 PM
🚨📣 #insidertrading Weill David bought $109.1K of $TMDX on 2026-09-11
Insider performance (2020-24):
🟢1d: 2%
🟢3d: 8%
🟢5d: 1%
🔴1m: -15%
🟢3m: 13%
🟢6m: 27%
🟢1y: 159%
total trade: 1
$SPY $QQQ $DIA $VIX
#stock
#stockmarket #NASDAQ #NYSE #OTC
Insider performance (2020-24):
🟢1d: 2%
🟢3d: 8%
🟢5d: 1%
🔴1m: -15%
🟢3m: 13%
🟢6m: 27%
🟢1y: 159%
total trade: 1
$SPY $QQQ $DIA $VIX
#stock
#stockmarket #NASDAQ #NYSE #OTC
🚨 $TMDX
On September 10, 2026, the Company issued a press release announcing the leadership transition.
On September 10, 2026, the Company issued a press release announcing the leadership transition.
SEC Filing: TMDX
Click to view the official SEC document.
www.sec.gov
September 10, 2026 at 8:41 PM
🚨 $TMDX
On September 10, 2026, the Company issued a press release announcing the leadership transition.
On September 10, 2026, the Company issued a press release announcing the leadership transition.